Противоишемическое, антиаритмическое и сосудистое действие ингибитора ангиотензинпревращающего фермента зофеноприла в эксперименте

1. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84–95.
2. Pinto YM, van Wijngaarden J, van Gilst WH et al. The effects of short- and long-term treatment with an ACE inhibitor in rats with myocardial infarction. Basic Res Cardiol (Suppl. 1) 1991; 96: 165–72.
3. Pfeffer MA, Pfeffer JM, Steinberg CR et al. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72: 406–12.
4. Sweet CS, Emmert SE, Stabilito II et al. Increased survival in rats with congestive heart failure treated with enalapril. J Cardiovasc Pharmacol 1987; 10: 636–42.
5. Hartman JC, Hullinger TG, Wall TM et al. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 1993; 234: 229–36.
6. Miki T, Miura T, Shimamoto K et al. Do angiotensin converting enzyme inhibitors limit infarct size? Clin Exp Pharmacol Physiol 1993; 20: 429–34.
7. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999; 17: 115–33.
8. Sacco G, Bigioni M, Evangelista S et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001; 414: 71–8.
9. Grover GJ, Sleph PG, Dzwonczyk S et al. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J Pharmacol Exp Ther 1991; 257: 919–29.
10. Liu X, Engelman RM, Ronson JA et al. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992; 6: 437–43.
11. Ferrari R, Cargnoni S, Curello C et al. Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: Insight into its mechanism of action. J Cardiovasc Pharmacol 1992; 20: 694–704.
12. Frascarelli S, Ghelardoni S, Ronca-Testoni S et al. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol 2004; 43: 294–9.
13. Tio AR, de Langen CD, de Graeff PA et al. The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drug Ther 1990; 4: 695–704.
14. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improved contractile function of stunned myocardium by different mechanisms of action. Am Heart J 1991; 121: 1319–30.
15. Ertl G, Kloner RF, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982; 65 (1): 40–8.
16. Black SC, Driscoll EM, Lucchensi BR. Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia with reperfusion. Pharmacology 1998; 57: 35–46.
17. Napoli C, Sica V, de Nigris F et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148 (1): е5.
18. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003; 482: 95–9.
19. de Nigris F, D'Armiento FP, Somma P et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81: 107–15.
20. Cominacini L, Pasini A, Garbin U et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15: 891–5.
21. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ (под ред. В.П.Фисенко). М.: Минздрав РФ, ЗАО "ИИА "Ремедиум", 2000.
22. Королев Д.В., Егорова Е.И., Александров И.В. и др. Автоматизация физиологического эксперимента, сопровождающаяся регистрацией основных гемодинамических показателей (PhysExp 2). Свидетельство об официальной регистрации программы для ЭВМ №2004612138 (зарегистрировано 17.09.04).
23. Сыренский А.В., Берштатский Б.Г. Оценка упруго-эластических свойств резистивных сосудов методом математического моделирования. Физиол. журнал. 1979; 65: 6.
24. Ertl G, Kloner RA, Alexander RW et al. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982; 65: 40–8.
25. Цырлин В.А., Шляхто Е.В., Нифонтов Е.М. и др. Влияние ингибитора ангиотензин-превращающего фермента спираприла на размер экспериментального инфаркта, выраженность ишемических тахиаритмий и ишемическую адаптацию миокарда. Кардиология. 2002; 41 (12): 91–5.
26. Miki T, Miura T, Ura N. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. J Am Coll Cardiol 1996; 28: 1616–22.
27. Liu X, Engelman RM, Ronson JA et al. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992; 6:437–43.
28. Shah AD, Arora RR. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors? Clin Cardiol 2005; 28: 551–5.
29. Grassi G, Seravalle G, Bertinieri G et al. Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. Acta Physiol Scand 2003; 177: 399–404.
30. Сонин Д.Л., Сыренский А.В., Галагудза М.М. Влияние ингибитора ангиотензин-превращающего фермента спираприла на статические и динамические параметры сосудистого тонуса в условиях эксперимента. Регионарное кровообращение и микроциркуляция. 2003; 2 (2): 58–62.
31. Сонин Д.Л., Сыренский А.В., Галагудза М.М. и др. Роль оксида азота в регуляции растяжимости артериальных сосудов у нормо- и гипертензивных крыс. Артериальная гипертензия. 2002; 6 (8): 200–2.
32. Walker MJ, Curtis MJ, Hearse DJ et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 1988; 22: 447–55.

Е.В.Шляхто, М.М.Галагудза, А.В.Сыренский, И.О.Блохин, И.М.Константинов, Е.М.Нифонтов

НИИ кардиологии им. В.А.Алмазова Федерального агентства по здравоохранению и социальному развитию, Санкт-Петербург; 
Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова